EC de-authorises vitamin and muscle claims in final article 13, draft regulation

By Shane Starling

- Last updated on GMT

EC de-authorises vitamin and muscle claims in final article 13, draft regulation
The European Commission has drafted the regulation that will bring into European law the final list of approved, article 13, general function health claims – with a specific reference to two approved claims that will not be authorised.

The EC has said all 2700+ approved and rejected claims will enter the EU law books in the first quarter of 2012. Six months later, all rejected claims will be barred in the European Union.

In the current draft regulation, positive claim opinions that fat consumption can benefit fat soluble vitamin absorption; and that sodium can benefit muscle function, will be outlawed on the grounds of their overall negative contribution to nutrition and health.

Conflicting and confusing message

Article 12 of the draft regulation states: Authorisation may also legitimately be withheld ifhealth claims do not comply with other general and specific requirements ofRegulation (EC) No 1924/2006 [the nutrition and health claims regulation], even in the case of a favourable scientific assessment.”

It said the fat-vitamins and sodium-muscle claims, “would convey a conflicting and confusing message to consumers, because it would encourage consumption of those nutrients for which, on the basis of generally accepted scientific advice, European, national and international authorities inform the consumer that their intake should be reduced.”

“Furthermore, even if the health claims concerned were to be authorised only under specific conditions of use and/or accompanied by additional statements or warnings, these would not be sufficient to alleviate the confusion of the consumer, and consequently the claims should not be authorised.”

Article 16 of the draft observes: Comments and positions from the members of the public and interested stakeholders, received by the Commission have been adequately considered when setting the measures provided for in this Regulation.”

Related news

Show more

Related products

show more

BB536 for optimal Gut health and beyond

BB536 for optimal Gut health and beyond

Content provided by Morinaga Milk Industry Co., Ltd. | 03-Oct-2024 | White Paper

Among the various probiotics strains available, Bifidobacterium longum BB536 stands out due to its well-documented safety, efficacy, and regulatory approvals....

Unlock sensory innovation with AromatiQ™ technology

Unlock sensory innovation with AromatiQ™ technology

Content provided by Lonza | 20-Sep-2024 | Product Brochure

With 70% of consumers willing to pay a premium for a more enjoyable and memorable supplement experience, Lonza’s new AromatiQ™ technology enables brands...

From Biofarma a clinically tested vaginal protection

From Biofarma a clinically tested vaginal protection

Content provided by Biofarma Group | 05-Sep-2024 | Product Brochure

Bacterial vaginosis is considered the most common cause of vaginal infection among pregnant and non-pregnant women. In this scenario, the oral intake of...

Related suppliers

Follow us

Products

View more

Webinars